New injection tested for rare kidney disease
NCT ID NCT05174221
Summary
This early-stage study tested the safety and effects of mezagitamab, an experimental injection, in 17 people with IgA nephropathy, a kidney disease. Participants received weekly injections for 8 weeks, then every 2 weeks for 16 weeks, while continuing their standard medications. The main goal was to check for side effects and see how the body processes the drug, with follow-up monitoring for up to 96 weeks for some participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia
Brescia, Lombardy, 25123, Italy
-
Ajou University Hospital
Suwon, 16499, South Korea
-
Amicis Research Center - Northridge - Nordhoff
Northridge, California, 91324, United States
-
Beijing Friendship Hospital,Capital Medical University
Beijing, Beijing Municipality, 100050, China
-
Boise Kidney and Hypertension Institute - Frenova
Nampa, Idaho, 83687, United States
-
Core Research Group
Milton, Queensland, 4064, Australia
-
Fujita Health University Hospital
Toyoake-shi, Aiti, 470-1192, Japan
-
Fundacio Puigvert
Barcelona, 8025, Spain
-
Guangdong Provincial Peoples Hospital
Guangzhou, Guangdong, 510080, China
-
Hiroshima University Hospital
Hiroshima, Hiroshima, 734-8551, Japan
-
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008, Spain
-
Hospital Universitario Vall d'Hebron - PPDS
Barcelona, 08035, Spain
-
Hull Royal Infirmary
Hull, HU3 2JZ, United Kingdom
-
Kasugai Municipal Hospital
Kasugai-Shi, Aiti, 486-0804, Japan
-
Leicester General Hospital
Leicester, Leicestershire, LE5 4PW, United Kingdom
-
Monash Health, Monash Medical Centre
Clayton, Victoria, 3168, Australia
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
National University Hospital- Singapore
Singapore, 119074, Singapore
-
NorthShore University HealthSystem
Evanston, Illinois, 60201, United States
-
Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
-
Sapporo City General Hospital
Sapporo, Hokkaido, 060-8604, Japan
-
Semmelweis Egyetem
Budapest, 1083, Hungary
-
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, 03080, South Korea
-
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
Szeged, Csongrád megye, 6720, Hungary
-
Taipei Medical University Shuang Ho Hospital
New Taipei City, 23561, Taiwan
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
Conditions
Explore the condition pages connected to this study.